David A. Siegel Bio Atla, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Bio Atla, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 14,100 shares of BCAB stock, worth $9,588. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,100
Previous 188,900
92.54%
Holding current value
$9,588
Previous $66,000
92.42%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding BCAB
# of Institutions
42Shares Held
13.5MCall Options Held
20.7KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.84MShares$3.29 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.78MShares$1.21 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.49MShares$1.01 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.37MShares$934,3710.03% of portfolio
-
Black Rock Inc. New York, NY792KShares$538,2600.0% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $24.7M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...